Published in final edited form as:

Clin Exp Allergy. 2015 December ; 45(12): 1856–1867. doi:10.1111/cea.12643.

Different Bla-g T cell antigens dominate responses in asthma versus rhinitis subjects

Myles B.C. Dillon, PhD^a, Veronique Schulten, PhD^a, Carla Oseroff, MS^a, Sinu Paul, PhD^a, Laura M. Dullanty, BA^a, April Frazier, PhD^a, Xavier Belles, PhD^b, Maria-Dolors Piulachs, PhD^b, Cynthia Visness, PhD, MPH^c, Leonard Bacharier, MD^d, Gordon R. Bloomberg, MD^d, Paula Busse, MD^e, John Sidney, MS^a, Bjoern Peters, PhD^a, and Alessandro Sette, PhD^a

^aLa Jolla Institute for Allergy and Immunology, La Jolla, CA

^bInstitut de Biologia Evolutiva (CSIC-Universitat Pompeu Fabra), Passeig Marítim 37, 08003 Barcelona, Spain

^cRho Inc. Federal Systems Division, Chapel Hill, NC

^dWashington University School of Medicine, Department of Pediatrics, St. Louis, MO

^eIcahn School of Medicine at Mount Sinai School of Medicine, Division of Clinical Immunology, New York, NY

Abstract

Background and Objective—The allergenicity of several German cockroach (Bla-g) antigens at the level of IgE responses is well established. However less is known about the specificity of CD4⁺ T_H responses, and whether differences exist in associated magnitude or cytokine profiles as a function of disease severity.

Methods—Proteomic and transcriptomic techniques have been employed to identify novel antigens recognized by allergen-specific T cells. To characterize different T_H functionalities of allergen-specific T cells, ELISPOT assays with sets of overlapping peptides covering the sequences of known allergens and novel antigens were employed to measure release of IL-5, IFN γ , IL-10, IL-17, and IL-21.

Results—Using these techniques, we characterized T_H responses in a cohort of adult Bla-g sensitized subjects, either with (n=55) or without (n=17) asthma, and non-sensitized controls (n=20). T cell responses were detected for ten known Bla-g allergens and an additional ten novel Bla-g antigens; representing in total a 5-fold increase in the number of antigens demonstrated to be targeted by allergen-specific T cells. Responses of sensitized individuals regardless of asthma status were predominantly T_H2, but higher in patients with diagnosed asthma. In asthmatic subjects Bla-g 5, 9 and 11 were immunodominant while, in contrast, non-asthmatic sensitized subjects responded mostly to Bla-g 5, 4, and the novel antigen NBGA5.

Corresponding author: Myles Dillon, 9420 Athena Circle, La Jolla, CA 92037, (858) 752-6942, myles@liai.org.

Conflict of Interest: The authors have no conflict of interest to declare.

Conclusions—Asthmatic and non-asthmatic cockroach sensitized individuals exhibit similar T_H2 polarized responses. Compared to non-asthmatics, however, asthmatic individuals have responses of higher magnitude and different allergen specificity.

Keywords

Cockroach allergy; asthma; epitope; $CD4^+$ T cell

INTRODUCTION

The German cockroach (*Blattella germanica*; Bla-g) is a common allergen among inner-city children and a significant health problem worldwide (1,2). Bla-g allergies strongly correlate with asthma development, and early exposure leads to increased Bla-g sensitization and asthma severity (1,3-6).

Several studies defined Bla-g allergens on the basis of IgE reactivity from sensitized individuals (7-16), and correlated of seroreactivity prevalence with severity of Bla-g allergies (2,17). However, investigation of cellular responses is limited to few of the known Bla-g allergens, with relatively few T cell epitopes identified (18,19). Here, we report a systematic analysis of T cell responses to all known Bla-g allergens.

We previously used a transcriptomic/proteomic approach to identify novel antigens and T cell epitopes in Timothy grass (TG) allergy (20). This indicated that T_H2 cell reactivity is not necessarily limited to proteins recognized by IgE, but extends to proteins recognized by IgG and/or generally abundant in the pollen extract. Here, we investigated whether a similar approach could reveal new Bla-g T cell antigens.

Bla-g allergies are associated with clinical presentations, ranging from allergic rhinitis (AR) without asthmatic symptoms, to asthma severity ranging from intermittent (IA), to mild, moderate (MMA), and severe (SA) (2,21). While some studies have examined the prevalence of IgE reactivity in populations, if not relative titers (22), against different Bla-g allergens, most studies have focused primarily on IgE reactivity to whole Bla-g extract or one or two individual allergens.

Here, we planned to use the epitope information derived from the analysis of known and novel Bla-g allergens combined, to assess whether different disease severities are associated with differential magnitude, functionality, or antigen/epitope specificity at the level of T cell responses. Allergen-specific T cell responses are usually dominated by T_H2 type responses, with IL-5 secreted at the highest levels, followed by IL-13, IL-4, and IL-9 (23,24), although involvement of different T helper subsets has also been reported. Elevated T_H17 cells have been described, particularly in the context of asthmatic reactions, as IL-17F production has been reported as increased in numerous asthmatic states (25,26). T_R1 cells secreting IL-10 have been implicated in negative regulation of T cell allergic responses (27). The balance between T_H2 cells and $IFN\gamma$ -producing T_H1 cells (T_H1/T_H2 polarization) is considered a potential key determinant in regulating allergic disease (1,28). Finally, recent studies have described T_{FH} cells, associated with production of IL-21, as key regulators of isotype switch

(including IgE) (29). Here, we accordingly sought to characterize the relative balance of IFN γ , IL-5, IL-10, IL-17, and IL-21, production in response to Bla-g derived epitopes.

MATERIALS AND METHODS

Study Subject Populations

Subjects displaying symptoms of allergic rhinitis (e.g., stuffed, blocked, or runny nose, sneezing, itching or watery eyes, or itching nose or throat) were recruited from St. Louis, New York City, Boston, and Cleveland clinics, following Institutional Review Board approved protocols and informed consent. Subjects with positive skin-prick test (wheal ≥ 3 mm) and IgE titers (≥ 0.35 kUA/L by ImmunoCAP assay) toward Bla-g extract were classified as Bla-g IgE-sensitized. Non-sensitized controls were individuals with negative skin-prick tests and IgE titers to Bla-g extract. No information about pollen and HDM allergies is included as this data was not during the clinical study. The asthmatic status of Bla-g sensitized subjects was further classified as:

- 1) Allergic rhinitis and no asthma (AR): no self-reported asthma.
- 2) Intermittent asthma (IA): no controller treatment and no exacerbations in the last 12 months.
- 3) Mild or moderate asthma (MMA), further sub-divided as:
 - 3a) Mild asthma: current treatment (total daily dose of inhaled steroids) of fluticasone hydrofluoroalkane-134a (HFA) ≤ 264 μ g or fluticasone dry powder inhaler (DPI) ≤ 300 μ g or equivalent AND no prednisone bursts in last 12 months.
 - 3b) Moderate asthma: current treatment of fluticasone HFA 264-440 μ g or fluticasone DPI 300-500 μ g or equivalent and 0 prednisone bursts in last 12 months OR 1 prednisone burst in last 12 months and current therapy of fluticasone HFA ≤ 440 μ g or fluticasone DPI ≤ 500 μ g or equivalent.
- 4) Severe asthma (SA): current treatment of fluticasone HFA >440 μ g or fluticasone DPI >500 μ g or equivalent OR >1 prednisone burst in last 12 months.

Bla-g sensitized individuals who did not meet the criteria for clear diagnosis of asthma and/or allergic rhinitis were excluded. Cohort information is summarized in **Supplemental Table 1**. Subject information is in **Supplemental Table 2**.

Generation of the Bla-g Transcriptome

Bla-g females used for the whole transcriptome analysis were reared at the Institut de Biologia Evolutiva (CSIC-UPF) at 30 °C and 70% humidity, supplied with water *ad libitum* and commercial dog food diet. Whole transcriptome was analyzed in fat body, ovary, and epidermis. Fat body and ovaries were from 3 to 5-day-old adults, while the epidermis was from the thoracic dorsum of 5 and 6-day-old 6th instar nymphs. Total RNA was extracted with the GenElute™ Mammalian Total RNA Miniprep Kit (Sigma-Aldrich). RNA samples

were sequenced at GATC-Biotech (Konstanz, Germany) by Roche™ pyrosequencing technology (454) (2,17,30,31). Data is accessible at the GEO database (accession code GSE63921).

Proteomic Analysis of Bla-g Extract

Novel Bla-g antigens were identified as described for TG (20). Briefly, Bla-g extract (Greer, cat#XPB46D3A4) and pooled sera from 15 Bla-g sensitized subjects were submitted to Applied Biomix for 2-D immunoblot analysis. Gels (3–10 pH range, 12% (vol/vol) acrylamide) of Bla-g extract were incubated with pooled sera, stained with goat anti-human IgE and rabbit anti-human IgG (Sigma-Aldrich), and visualized by using Cy2-conjugated donkey anti-goat IgE and Cy5-conjugated donkey anti-mouse IgG antibodies (Biotium). This was followed by mass spectrometry analysis of positive IgE and/or IgG protein spots. MALDI spectra were compared against the Bla-g transcriptome using Mascot. 16 unique novel potential ORFs were identified (**Supplemental Table 3**). For a more detailed description of proteomic identification, see **Supplemental Methods**.

Peptide Synthesis and MHC Class II Binding Predictions

809 15-mer peptides overlapping by 5 residues were synthesized, covering Bla-g allergens, Bla-g 1-2, 4-9 and 11. An additional 646 15-mer peptides predicted promiscuous binders for to HLA class II (32) were synthesized from the proteomic identified sequences. Finally, 233 predicted promiscuous 15-mer peptides from recently identified antigens (Vitellogenin, Hsp60, Enolase, Triosephosphate Isomerase (TPI), Trypsin, and RACK1) were synthesized (**Supplemental Table 4**). For detailed description of binding prediction and peptide synthesis, see **Supplemental Methods**.

PBMC Isolation, Cell Cultures, and ELISPOT Assays

PBMC (peripheral blood mononuclear cells) were isolated from 450 mL of blood by density gradient centrifugation and cryopreserved, as described (19). Upon thaw of cryopreserved vials, according to our standard SOP viability of cells was determined with trypan blue staining, and only subjects with >85% viability were included in the study. Specifically, the average viability was $97 \pm 2\%$. Our goal in the use of PBMC was to maintain physiological APC to T cell interactions. Furthermore, using purified T cells would require additional manipulations and higher number of starting cells. Accordingly, for several donors we would not have had enough cells to complete the screen. For these reasons we chose to utilize whole unfractionated PBMC in our assays. Next, 1×10^5 cells per well were incubated with peptide, peptide pool, or Bla-g extract (10, 5, and 10 ug/ml, respectively) on anti-cytokine antibody coated ELISPOT plates (Millipore #MSIPS4510) for 22 hours. Subsequently, production of IFN γ , IL-5, IL-17 and IL-10, and IL-21 in response to peptide stimulation was measured by ELISPOT, as described previously (19,20). For IL-21, similar procedures were used and anti-IL-21 clone MT21.4/821 and anti-IL-21-biotin clone MT21.3m (Mabtech) were used. Each peptide pool and individual peptides were run in triplicate. Criteria for peptide pool positivity were at least 100 spot forming cells (SFC) per 10^6 PBMC, $p < 0.05$ by Student's t-test when compared to negative control, and stimulation index ≥ 2 . Criteria for peptide positivity were identical except with a threshold of 20 SFC.

These criteria have been used consistently in previous studies and have been maintained for consistency (20,33-38). We consider 20 SFC/10⁶ PBMC as an operational lower limit of detection in our ELISPOT assay, and is thus used as the “negative” value for donor response, and is used where a lower limit value is required for graphical or statistical purposes.

RESULTS

Differential Immune Reactivity Against Known Bla-g Allergens (BLAGA) in Sensitized Versus Non-sensitized Controls

A cohort of 90 adult subjects was recruited from clinical sites in St Louis, New York City, Boston, and Cleveland (summarized in **Supplemental Table 1**). Individual subject information is listed in **Supplemental Table 2**. The study population was 77%: 23% female to male and had a median age of 33 ($\pm$ 10; range 19-56), reflecting the fact that subjects were recruited at pediatric clinics as parents of allergic children. In this population, single female parents were prevalent. Adult subjects were included in the study due to the relatively large (450 ml) volume of blood required for the epitope identification studies. Each subject was classified as either Bla-g sensitized (Bla-g IgE titer $\geq$ 0.35 kUA/L and skin prick test wheal $\geq$ 3 mm) or control ($<$ 0.35 Bla-g IgE titer and negative skin prick test). The 20 control subjects were all non Bla-g sensitized and either not associated with clinical sign of asthma (n=13) or associated with intermittent (n=5) or moderate (n=2) asthma. Sensitized subjects had average wheal of 6.1 mm and average IgE of 10.1 kUA/L. No information about pollen and HDM allergies was available, as this data was not collected during the clinical study. Bla-g sensitized subjects were classified as AR, IA, MMA, or SA based on clinical history, questionnaires, and medication scores as detailed in the Methods section. Specific treatment information is also listed in **Supplemental Table 2**.

We synthesized sets of 15-mer peptides, overlapping by 10 amino acids covering the entire sequences of known Bla-g allergens, i.e. Bla-g 1-2, 4-7, 9 and 11, referred hereafter as BLAGA. A total of 809 BLAGA peptides were pooled for screening, encompassing on average 20 peptides per pool.

To assess T cell reactivity, we utilized a strategy previously applied to the definition of epitopes from various allergens (19,20). Here, PBMC from each subject were stimulated *in vitro* with Bla-g extract. After 14 days, pools of overlapping 15-mer peptides were tested, and positive pools deconvoluted to identify the specific epitopes. As readout, we utilized ELISPOT assays specific for IL-5, IFN γ , IL-10, IL-17 and IL-21, chosen as representative of T_H2, T_H1, T_R1, T_H17 and T_{FH} reactivity, respectively. To validate that cryopreservation subsequent to gradient centrifugation of PMBC did not affect the response of the T cell to peptide stimulation as compared with non-frozen PBMC, we assayed T cell response in three Bla-g sensitized subjects (**Supplemental Figure 1**). PBMC were isolated and half of the samples were cryopreserved in FBS with 20% DMSO in liquid nitrogen for one week while the other half of the PBMC were immediately cultured without freezing with pools of Bla-g peptides (described below as “Disease-Specific Pools”). After 14 days, the PBMC were stimulated with the Disease-Specific Pools and IL-5, IFN γ , IL-10, IL-17 and IL-21 release was measured by ELISPOT. As shown in **Supplemental Figure 1**, the sums of

cytokine release for the cryopreserved PBMC (Frozen) were statistically equivalent ($p > 0.05$) to the non-frozen PBMC (Fresh). Thus, we concluded that measuring cytokine release subsequent to cryopreserving the PBMC was a valid technique to utilize for our Bla-g epitope screen. Vigorous overall T cell responses (expressed as total SFC/ 10^6 PBMC for all BLAGA and for all cytokines) were detected against BLAGA in sensitized donors (**Figure 1A**). As expected, the non-sensitized controls were associated with lower responses. In sensitized donors, Bla-g 4, 5, 9, and 11 were immunodominant (**Figure 1B**). However, in non-sensitized controls Bla-g 5 and 11 were hardly recognized.

As expected, the most dominant cytokine detected in sensitized individuals was IL-5 (**Figure 1C**), followed by IL-10 and IFN γ . Lower or absent levels of IL-5, IFN γ and IL-10 were seen in non-sensitized controls. Lower levels of IL-17 and IL-21 were also detected, with no significant difference between sensitized and control individuals.

Definition of Novel Bla-g T cell Antigens

In the experiments above, 44% of sensitized subjects responded to extract stimulation but not to any of the BLAGA peptides (data not shown). This suggested that additional uncharacterized antigenic proteins might be present in the extract.

Here we utilized a recently described approach based on proteomic analysis combined with HLA-binding predictions (20) to identify novel Bla-g antigens (NBGA). Transcripts from Bla-g mRNA were deep-sequenced, followed by mass spectrometry analysis of individual protein spots from 2-D gels of Bla-g extract to derive sequences (**Figure 2**). These transcripts, along with the MALDI-derived peptide sequences, were assembled in 16 unique novel potential ORFs, referred to hereafter as NBGA 1-16 (**Supplemental Table 3**). Using similar proteomic techniques, six additional NBGA, including Enolase, Hsp60, RACK1, TPI, Trypsin and Vitellogenin, were independently identified (15,39).

In total, these studies defined 22 different NBGA, 15 of which were IgE reactivity as defined by the 2-D immunoblot analysis (**Figure 2**) and previous studies (15,18,19,39). Promiscuous HLA class II binding peptides were predicted as previously described (20,33) and a total of 879 peptides were synthesized. Cytokine release in response to each peptide following 2-week *in vitro* extract stimulation was measured as above. A total of 13 NBGA were associated with detectable cytokine release in more than one subject (**Figure 3A**). While the novel antigen NBGA1 dominated the response (**Figure 3A**), significant reactivity was also observed for several others, including NBGA2-5, NBGA7, TPI and RACK1. By contrast, ten other antigens (NBGA8-16 and vitellogenin) were negative for any cytokine responses.

Remarkably, most of the reactivity was encompassed by IgE-reactive (IgE+) NBGA (shown in the left of **Figure 3A**), while, with exception of the NBGA5, IgE-unreactive (IgE-) NBGA (shown in the right of **Figure 3A**) were essentially negative. IgE+ NBGA reactivity for all cytokines was stronger compared to IgE- NBGA (**Figure 3B**). Non-sensitized control subjects also preferentially recognized IgE+ NBGA, but with lower magnitudes (**Figure 3B**).

Breadth and Immunodominance at the Epitope Level

Overall, 356 non-redundant epitopes recognized in at least one subjects were identified. A total of 56% of the sensitized subjects recognized at least one BLAGA epitope. Combining BLAGA and NBGA epitopes increased the percentage of subjects recognizing at least one epitope to 79% (**Figure 4A**). Thus, combined use of epitopes derived from BLAGA and NBGA achieves greater coverage of Bla-g sensitized individuals.

Overall, 50% of the subjects recognized 6 peptides or more (**Figure 4A**). 90% of the total response was encompassed by the top 164 epitopes, and the top 23 epitopes captured 50% of the total response (**Figure 4B**). These 164 epitopes, the corresponding average magnitudes and response frequencies, are listed in **Supplemental Table 5**.

Polarization of T cell Responses Correlates with Sensitization Status, While Magnitude of T Cell Responses Correlates with Asthma Status

Next, we correlated magnitude and functionality of T_H responses with sensitization and asthma status (**Figure 5**). Similar to what was observed for TG (20,33,40) allergy, the cytokine patterns in Bla-g sensitized patients was polarized, with responses dominated by IL-5, regardless of the AR versus asthma status of the sensitized donors. By contrast, responses in control subjects were not polarized, with similar proportions of IL-5 (32%), IFN γ (21%) and IL-10 (25%) being detected.

A response magnitude of 251 SFC/10⁶/donor cells was noted in non-sensitized controls (**Figure 5**). The response/donor of all asthmatic subjects combined were significantly higher than controls ($p<0.05$). The magnitude of responses progressively increased in AR subjects (491 SFC), patients with IA (605 SFC), and MMA (1786 SFC, $p<0.005$ to controls). Responses were somewhat lower in SA (1134 SFC), although still significantly higher than the control group ($p<0.05$), perhaps reflective of the immunosuppressive treatments administered to the SA group, as subjects in this group received regular higher doses of steroids (either >440 μ g of fluticasone HFA or >500 μ g of fluticasone DPI or equivalent OR >1 prednisone burst in last 12 months, as described in the Study Subject Population in the Materials and Methods) than the less severe asthma groups.

We examined whether different clinical groups also display differences in IgE levels. As shown in **Supplemental Figure 2a**, no significant difference in IgE titer to whole Bla-g extract was apparent between the different allergic groups. Here, we calculated the correlation between T cell responses and IgE titers (**Supplemental Figures 2b-c**). While T cell responses tend to increase as a function of both total response and IL-5 responses, these trends were not significant, thus confirming the previous findings (19,20).

Differential Immunodominance of BLAGA and NBGA in Control, Rhinitis and Asthmatic subjects

We next investigated the immunodominance patterns for BLAGA and NBGA antigens. **Table 1** lists percentages of subjects responding and average total response/donor associated with each particular antigen. **Figure 6** shows the same data in a pie chart format, with study subjects divided in non-sensitized controls, sensitized non-asthmatics, and sensitized

asthmatics. We expected, based on the data shown in **Figures 1 and 3**, different pattern of immunodominance between sensitized and non-sensitized individuals.

Indeed, in non-sensitized controls >70% of the total response was encompassed by the two antigens, Bla-g 9 and NBGA1 (**Figure 6A and Table 1**). In AR subjects (**Figure 6B and Table 1**) NBGA1 still encompassed a significant proportion of the response (21.3%), however Bla-g 4 was the most dominant (31.8% of response), and the response to Bla-g 5 (21.6%) was equivalent to that seen in NBGA1 (21.3%). The pattern further shifted in the sensitized asthmatic donors (**Figure 6C and Table 1**). Bla-g 5 and NBGA1 still accounted for large proportions of the response (32.7% and 11.9%, respectively), but responses to Bla-g 4 were nearly absent (1.6%). Responses to Bla-g 9 increased to 24.4%, and Bla-g 11, which had low responses in controls and rhinitis, increased to 8.1%.

Bla-g 2, which is a dominant target of IgE responses along with Bla-g 5, accounted for a minor fraction (<1%) of T cell reactivity among both rhinitis and asthmatic subjects, highlighting the lack of correlation between immunodominance for IgE and T cell responses, in agreement with previous reports in other allergies (19,33,36).

As observed in **Figure 5** in terms of the total response to all antigens, IL-5 was the dominant cytokine detected in both rhinitis and asthmatic subjects for the immunodominant antigens Bla-g 4, 5, 9, 11 and NBGA1 (**Table 2**), encompassing at least 50% of the response to each antigen. In control subjects, the response to the immunodominant antigens was less polarized to IL-5 as representative of T_H2 cytokines. $IFN\gamma$ responses were in general the second most vigorous response, accounting for 5-18% of the response in the various antigens and sensitized donors. NBGA1 is an important antigen in the three groups and responses were polarized to IL-5 in sensitized AR and asthmatic donors and to $IFN\gamma$ in controls. In the case of Bla-g 9, similar polarization was noted in AR and asthmatic subjects, with 65-70% of the response accounted by IL-5, and 4-16% of the responses accounted by other cytokines; this contrasts with what was observed in control subjects, where 45% of the response was accounted by IL-17, and only 30% of the response was accounted by IL-5. We additionally note a relatively high IL-10 response (31.1% of the total) to Bla-g 4 response in AR, whereas IL-10 to Bla-g 4 was negligible in asthmatics. In contrast, IL-10 Bla-g 5 responses in asthmatics accounted for 16.7% of the total, but were nonexistent in AR.

Only minor differences were observed in the pattern of responsiveness amongst different asthma severities. For example, NBGA1 and 7 were recognized most prominently in IA subjects (**Table 1**), but overall similar patterns were observed in the different categories of asthmatic patients. No significant differences linked to age were observed between subjects or groups, and thus the differences observed were consistent of a large range of ages. Additionally, the differences in response between groups was not due to heterogeneity of class II MHC between groups as no class II MHC allele was found to be significantly associated with asthmatic or rhinitis subjects.

Differential Recognition with Disease Specific Epitope Pools

Based on the above results, we hypothesized that the epitopes identified could be partitioned into sets associated with preferential recognition by specific patient groups. The *in silico*

analysis shown in **Supplemental Table 6** defines a set of 55 epitope sequences accounting for 84% of the total response in the rhinitis subjects, but only 20% of the response of asthmatic subjects. Similarly, a set of 147 epitopes (Asthmatic Set) could be identified that is associated with preferential recognition (55% of total response) in subjects with asthma, as compared to rhinitis subjects (5%).

We next validated whether pools of peptides corresponding to these different epitope sets were indeed differentially recognized in Bla-g sensitized subjects. PBMC from AR and asthmatic subjects were cultured *in vitro* for 14-days in the presence of Bla-g extract, followed by overnight assay with epitope pools described in **Supplemental Table 6**, and responses were measured by ELISPOT. The fraction of total response attributed to each epitope set was calculated.

The mean percentage of responses of asthmatic subjects was highest in response to the Asthma Pool as compared to either the Control or Rhinitis Pool (**Figure 7A**). In fact, in 12 of 14 responses from asthmatic subjects the highest response was directed to the Asthma Pool. Conversely, six of the seven responses in the AR (sensitized but non-asthmatic) subjects were dominated by the Rhinitis Pool (**Figure 7B**). The discrimination achieved with the disease-specific epitope pools between AR and asthmatic subjects was statistically significant ($p=0.0032$ by Fisher's Exact test). Results were similar when absolute magnitude of responses were considered (**Figures 7C-D**).

DISCUSSION

In this study we characterized CD4⁺ T cell responses in Bla-g allergy as a function of sensitization and asthmatic status, at the antigen and epitope level, and at the level of functionality of associated T cell responses. Surprisingly, we observed differences in antigens dominantly recognized in Bla-g sensitized subjects with and without asthma. To the best of our knowledge, this represents the first report of differential recognition between asthmatic and non-asthmatic subjects of T cell antigens in respiratory allergens in general, and Bla-g sensitized individuals in particular.

While further studies are necessary to address the mechanisms involved, it is possible to speculate why different antigens would be targeted in different forms of allergic disease. Since the different patterns of immunodominance are seemingly not related to intrinsic immunogenicity at the antigen level, it is possible that Bla-g antigens might be differentially processed and presented in the lung/bronchial versus the nasal environment, resulting in characteristically different immuno-signatures. Alternatively, differences in the local microbiome in the two anatomical locations might influence the specificity patterns of allergic reactions.

These studies were enabled by a large-scale epitope identification screening strategy. Overall, the study investigated the reactivity of approximately 1,600 different Bla-g-derived synthetic peptides. Over 164 different epitopes were recognized in multiple donors, and 23 accounted for 50% of the total response. Previous to the present study, the nature of human T cell epitopes had not been systematically investigated in this allergy system and only 30

Bla-g T cell epitopes had been described (19,23,24). Accordingly, our study greatly expanded the number of epitopes available for future studies dissecting the role of T cell responses in Bla-g allergies.

Initially, we investigated the conventional allergens, Bla-g 1, 2, 4-7, 9 and 11. Since these allergens only accounted for responses in 56% of Bla-g sensitized individuals, we employed a transcriptomic/proteomic approach with Bla-g extract and sera from Bla-g sensitized individuals to find the “missing” allergens. We previously used a similar approach in TG allergy to discover novel antigens associated with T cell reactivity (20,25,26). Here, we identified 16 novel Bla-g antigens (NBGA) that had IgE and/or IgG reactivity in Bla-g sensitized serum, and re-identified additional antigens recently described by others (15,27,39). These NBGA induced T cell responses in 43% of Bla-g sensitized subjects, and the combined sets of antigens were recognized by more than 79% of subjects. Since the proteomic approach was successfully applied to identification of both TG and Bla-g allergens, it is reasonable to assume that it might be applicable to other allergy systems as well.

In contrast to what we detected for TG allergy, the non-IgE reactive antigens in Bla-g extract had negligible T cell activity in all CD4⁺ subsets, suggesting a strong link between IgE and T cell activity in Bla-g allergy. It is not apparent why different allergic species would have different patterns in T cell:IgE linkage at the antigen level. One possibility is that the T cell responses to TG epitopes from antigens that are not targeted by IgE are actually cross-reactive T cell responses specific for antigens from other pollen species that are targeted by IgE. Indeed, we found that many TG epitopes show high cross-reactivity to other grass pollens (Westernberg et al., submitted). For Bla-g antigens, a lesser degree of exposure to homologous antigens from other species may explain the stronger T cell:IgE linkage observed.

While the data supports the notion that the antigens recognized by IgE and T cell responses are largely overlapping, IgE reactivity is not predictive of which antigens will be immunodominant at the level of T cell responses. We observed that the Bla-g 2 allergen, known to be a dominant antigen in terms of IgE responses, accounted for less than 4% of the total CD4⁺ T cell response to the Bla-g antigens. Conversely, allergens less dominant at the IgE level, such as Bla-g 9, Bla-g 4 and NBGA1 were immunodominant for T cell responses and accounted cumulatively for more than 75% of the response. Similar observations were previously reported (19,34). Along the same lines the NBGA5 antigen was recognized at the T cell level, despite not being targeted by IgE responses. Overall, the data suggests that specific allergen immunotherapy approaches aimed at modulating T cell responses might not need to target the most dominant IgE-binding proteins. Indeed, targeting the most dominant T cell antigens that are less prominent in terms of IgE-binding might offer an effective and safer immunotherapeutic approach.

In terms of functionality and magnitude of T cell responses, as expected, in the sensitized donors, the majority of the response was polarized to the T_H2 subset, but significant responses were also detected for other cytokines. Furthermore, in contrast to recent reports on the correlation between T_H17 responses and asthma (26), the relative contribution of

IL-17 response to Bla-g antigens was equivalent between AR and asthmatic groups. The magnitude of responses was progressively increased in AR subjects, IA, and MMA. Responses were somewhat lower in SA group, perhaps reflective of the immunosuppressive nature of medications administered to the SA group. Further analysis of the functionality of the specific T helper response between the subject groups could be determined through the use of epitope-loaded tetramers, however the process is not straightforward, given that the large heterogeneity of epitopes recognized would dictate the generation of a large number of tetramers, and that the restriction of the epitopes has not yet been determined. The present study required screening the reactivity of 90 donors for 1688 peptides and 5 cytokines. Therefore the ELISPOT assay was utilized because of its amenability to high-throughput analysis of large number of samples. The identification of the specific epitopes described herein will enable additional experiments using intracellular staining for subset-specific transcription factors (GATA-3, T-bet, FoxP3, ROR- γ t), which would be useful to further assess the presence of T_H2, T_H1, T_{reg} and T_H17 cells, respectively, and further characterize the phenotype of the responding T_H subsets. Accordingly, more in-depth characterization will have to be addressed in future studies utilizing selected epitopes. The present study was focused on the complementary approach, namely the comprehensive definition of the epitopes and antigens recognized.

We utilized the observed preferences in antigen recognition associated with clinical status, to develop epitope sets that differentiate between rhinitis and asthmatic Bla-g sensitized subjects. These epitopes could be used to isolate the corresponding allergen-specific cells and examine whether differences exist at the level of their transcriptional or epigenetic profiles, or whether changes in the associated signatures might precede or follow the evolution of allergic disease, asthma remission or exacerbation. While further validation and optimization is necessary, it is possible to speculate that these epitope sets may have diagnostic value, in providing a standardized laboratory test for asthmatic status.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

Samples and coordination support by the Inner City Asthma Consortium (ICAC); Madison: Bill Busse, Patrick Heinritz; St. Louis: Beth Tesson; New York: Diego Chiluisa, Janette Birmingham; Boston: Aleena Banerji, Ashley Keogh, Suraj Krishnamurthi, Mira D'Souza; Rho: Pat Zook, Derek Lawrence, Melissa Yaeger, Sam Arbes

This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract numbers HHSN272200900052C and HHSN272201000052I and grant numbers 1UM1AI114271-01 and U19AI100275.

ABBREVIATIONS

AR	Allergic rhinitis
BLAGA	<i>Blattella germanica</i> allergen

DPI	Dry powder inhaler
HFA	Hhydrofluoroalkane-134a
IA	Intermediate asthma
MALDI	Matrix-assisted laser desorption/ionization
MMA	Mild/moderate asthma
NBGA	Novel Bla-g antigen
ORF	Open reading frame
PBMC	Peripheral blood mononuclear cells
RACK1	Receptor for activated protein kinase C
SA	Severe asthma
SFC	Spot forming cells
TG	Timothy grass
TPI	Triosephosphate isomerase

REFERENCES

1. Kanchongkittiphon W, Mendell MJ, Gaffin JM, Wang G, Phipatanakul W. Indoor Environmental Exposures and Exacerbation of Asthma: An Update to the 2000 Review by the Institute of Medicine. *Environ Health Perspect.* Oct 10.2014
2. Camelo-Nunes IC, Solé D. Cockroach allergy: risk factor for asthma severity. *J Pediatr (Rio J).* Sep; 2006 82(5):398–9–authorreply399–400. [PubMed: 17028764]
3. Rosenstreich DL, Eggleston P, Kattan M, Baker D, Slavin RG, Gergen P, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. *N Engl J Med.* May 8; 1997 336(19):1356–63. [PubMed: 9134876]
4. Busse PJ, Wang JJ, Halm EA. Allergen sensitization evaluation and allergen avoidance education in an inner-city adult cohort with persistent asthma. *J Allergy Clin Immunol.* Jul; 2005 116(1):146–52. [PubMed: 15990788]
5. Wood RA, Togias A, Wildfire J, Visness CM, Matsui EC, Gruchalla R, et al. Development of cockroach immunotherapy by the Inner-City Asthma Consortium. *J Allergy Clin Immunol.* Mar; 2014 133(3):846–6. [PubMed: 24184147]
6. Lynch SV, Wood RA, Boushey H, Bacharier LB, Bloomberg GR, Kattan M, et al. Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children. *J Allergy Clin Immunol.* Sep; 2014 134(3):593–601. e12. [PubMed: 24908147]
7. Yi M-H, Jeong KY, Kim C-R, Yong T-S. IgE-binding reactivity of peptide fragments of Bla g 1.02, a major German cockroach allergen. *Asian Pac J Allergy Immunol.* Jun; 2009 27(2-3):121–9. [PubMed: 19839498]
8. Jeong KY, Lee J, Lee I-Y, Ree H-I, Hong C-S, Yong T-S. Allergenicity of recombinant Bla g 7, German cockroach tropomyosin. *Allergy.* Oct; 2003 58(10):1059–63. [PubMed: 14510726]
9. Pomés A, Vailes LD, Helm RM, Chapman MD. IgE reactivity of tandem repeats derived from cockroach allergen, Bla g 1. *Eur J Biochem.* Jun; 2002 269(12):3086–92. [PubMed: 12071974]
10. Shin KH, Jeong KY, Hong C-S, Yong T-S. IgE binding reactivity of peptide fragments of Bla g 4, a major German cockroach allergen. *Korean J Parasitol.* Mar; 2009 47(1):31–6. [PubMed: 19290089]
11. Jeong K-J, Jeong KY, Kim C-R, Yong T-S. IgE-binding epitope analysis of Bla g 5, the German cockroach allergen. *Protein Pept Lett.* May; 2010 17(5):573–7. [PubMed: 20044919]

12. Khurana T, Collison M, Chew FT, Slater JE. Bla g 3: a novel allergen of German cockroach identified using cockroach-specific avian single-chain variable fragment antibody. *Ann Allergy Asthma Immunol.* Feb; 2014 112(2):140–1. [PubMed: 24468254]
13. Un S, Jeong KY, Yi M-H, Kim C-R, Yong T-S. IgE binding epitopes of Bla g 6 from German cockroach. *Protein Pept Lett.* Sep; 2010 17(9):1170–6. [PubMed: 20394576]
14. Lee H, Jeong KY, Shin KH, Yi M-H, Gantulaga D, Hong C-S, et al. Reactivity of German cockroach allergen, Bla g 2, peptide fragments to IgE antibodies in patients' sera. *Korean J Parasitol.* Dec; 2008 46(4):243–6. [PubMed: 19127330]
15. Jeong KY, Kim C-R, Park J, Han I-S, Park J-W, Yong T-S. Identification of novel allergenic components from German cockroach fecal extract by a proteomic approach. *Int Arch Allergy Immunol.* 2013; 161(4):315–24. [PubMed: 23689614]
16. Arruda LK, Barbosa MCR, Santos ABR, Moreno AS, Chapman MD, Pomés A. Recombinant allergens for diagnosis of cockroach allergy. *Curr Allergy Asthma Rep.* Apr.2014 14(4):428. [PubMed: 24563284]
17. Arruda LK, Vailes LD, Ferriani VP, Santos AB, Pomés A, Chapman MD. Cockroach allergens and asthma. *Journal of Allergy and Clinical Immunology.* Mar; 2001 107(3):419–28. [PubMed: 11240940]
18. Chen H, Yang H-W, Wei J-F, Tao A-L. In silico prediction of the T-cell and IgE-binding epitopes of Per a 6 and Bla g 6 allergens in cockroaches. *Mol Med Rep.* Oct; 2014 10(4):2130–6. [PubMed: 25050891]
19. Oseroff C, Sidney J, Tripple V, Grey H, Wood R, Broide DH, et al. Analysis of T cell responses to the major allergens from German cockroach: epitope specificity and relationship to IgE production. *The Journal of Immunology.* Jul 15; 2012 189(2):679–88. [PubMed: 22706084]
20. Schulten V, Greenbaum JA, Hauser M, McKinney DM, Sidney J, Kolla R, et al. Previously undescribed grass pollen antigens are the major inducers of T helper 2 cytokine-producing T cells in allergic individuals. *Proc Natl Acad Sci USA.* Feb 26; 2013 110(9):3459–64. [PubMed: 23401558]
21. Bassirpour G, Zoratti E. Cockroach allergy and allergen-specific immunotherapy in asthma. *Current Opinion in Allergy and Clinical Immunology.* Aug.2014 1
22. Pomés A, Arruda LK. Investigating cockroach allergens: aiming to improve diagnosis and treatment of cockroach allergic patients. *Methods.* Mar 1; 2014 66(1):75–85. [PubMed: 23916425]
23. Scadding G. Cytokine profiles in allergic rhinitis. *Curr Allergy Asthma Rep.* May.2014 14(5):435. [PubMed: 24633619]
24. Maes T, Joos GF, Brusselle GG. Targeting interleukin-4 in asthma: lost in translation? *Am J Respir Cell Mol Biol.* Sep; 2012 47(3):261–70. [PubMed: 22538865]
25. Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F. Th17 cells: new players in asthma pathogenesis. *Allergy.* Aug; 2011 66(8):989–98. [PubMed: 21375540]
26. Ota, K.; Kawaguchi, M.; Matsukura, S.; Kurokawa, M.; Kokubu, F.; Fujita, J., et al. *Journal of Immunology Research.* Hindawi Publishing Corporation; Apr 14. 2014 Potential Involvement of IL-17F in Asthma.; p. 1-8.
27. Zhang H, Kong H, Zeng X, Guo L, Sun X, He S. Subsets of regulatory T cells and their roles in allergy. *Journal of Translational Medicine.* 2014; 12:125. [PubMed: 24886492]
28. Schulten V, Oseroff C, Alam R, Broide D, Vijayanand P, Peters B, et al. The identification of potentially pathogenic and therapeutic epitopes from common human allergens. *Ann Allergy Asthma Immunol.* Jan; 2013 110(1):7–10. [PubMed: 23244651]
29. Crotty S. Follicular helper CD4 T cells (TFH). *Annu Rev Immunol.* 2011; 29:621–63. [PubMed: 21314428]
30. Mukherjee S, Berger MF, Jona G, Wang XS, Muzzey D, Snyder M, et al. Rapid analysis of the DNA-binding specificities of transcription factors with DNA microarrays. *Nat Genet.* Dec; 2004 36(12):1331–9. [PubMed: 15543148]
31. Kumar S, Blaxter ML. Comparing de novo assemblers for 454 transcriptome data. *BMC Genomics.* 2010; 11:571. [PubMed: 20950480]

32. Paul S, Lindestam Arlehamn CS, Scriba TJ, Dillon MBC, Oseroff C, Hinz D, et al. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. *Journal of Immunological Methods*. Apr 7.2015
33. Oseroff C, Sidney J, Kotturi MF, Kolla R, Alam R, Broide DH, et al. Molecular Determinants of T Cell Epitope Recognition to the Common Timothy Grass Allergen. *The Journal of Immunology*. Jul 2; 2010 185(2):943–55. [PubMed: 20554959]
34. Schulten V, Tripple V, Sidney J, Greenbaum J, Frazier A, Alam R, et al. Association between specific timothy grass antigens and changes in TH1- and TH2-cell responses following specific immunotherapy. *J Allergy Clin Immunol*. Nov; 2014 134(5):1076–83. [PubMed: 25042980]
35. Oseroff C, Sidney J, Vita R, Tripple V, McKinney DM, Southwood S, et al. T Cell Responses to Known Allergen Proteins Are Differently Polarized and Account for a Variable Fraction of Total Response to Allergen Extracts. *The Journal of Immunology*. Aug 2; 2012 189(4):1800–11. [PubMed: 22786768]
36. Lindestam Arlehamn CS, Sidney J, Henderson R, Greenbaum JA, James EA, Moutafsi M, et al. Dissecting Mechanisms of Immunodominance to the Common Tuberculosis Antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ). *The Journal of Immunology*. May 3; 2012 188(10):5020–31. [PubMed: 22504645]
37. Moutafsi M, Bui H-H, Peters B, Sidney J, Salek-Ardakani S, Oseroff C, et al. Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses. *J Immunol*. Jun 1; 2007 178(11):6814–20. [PubMed: 17513729]
38. Hinz D, Oseroff C, Pham J, Sidney J, Peters B, Sette A. Definition of a pool of epitopes that recapitulates the t cell reactivity against major house dust mite allergens. *Clin Exp Allergy*. Feb 5.2015
39. Chuang J-G, Su S-N, Chiang B-L, Lee H-J, Chow L-P. Proteome mining for novel IgE-binding proteins from the German cockroach (*Blattella germanica*) and allergen profiling of patients. *Proteomics [Internet]*. Nov; 2010 10(21):3854–67. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/pmic.201000348/abstract?jsessionid=9718A2AA03D40591B9C468E16B09A498.f02t04>.
40. Wambre E, Bonvalet M, Bodo VB, Maillère B, Leclert G, Moussu H, et al. Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4(+) T cell responses. *Clin Exp Allergy*. Feb; 2011 41(2):192–203. [PubMed: 21105918]

Figure 1. CD4⁺ T Cell Reactivity to Known Bla-g Allergens (BLAGA)

A) Overall responses (sum of peptide and cytokine responses) after stimulation with BLAGA peptides. B) Overall responses to individual BLAGA. C) Pattern of cytokine responses to BLAGA. Geometric means and 95% confidence intervals shown. Black circles represent Bla-g sensitized subjects, and gray open circles represent non-sensitized controls. * p 0.05, ** p 0.005 by non-parametric Mann-Whitney t-test. Dotted lines at 20 SFC indicates lower limit of assay detection. We consider 20 SFC/10⁶ PBMC as an operational lower limit of detection in our ELISPOT assay, and is thus used as the “negative” value for donor response, where a lower limit value is required for graphical or statistical purposes. Each symbol represents the response from an individual subject.

Figure 2. Identification of Novel Bla-g antigens (NBGA) by 2-D Gel Immunoblot

A) Coomassie stain of 2-D gel of Bla-g extract. B) Bla-g extract stained with pooled sera of Bla-g sensitized subjects. Green spots indicate IgE binding; red spots indicate IgG binding; and yellow spots indicate dual IgE/IgG binding. Yellow circles indicate sections selected for proteomic analysis.

A

B

Figure 3. CD4⁺ T Cell Reactivity to Novel Bla-g Antigens (NBGA)

A) Individual NBGA responses (sum of all cytokines) of Bla-g sensitized and control subjects after stimulation with NBGA peptides. B) Pattern of cytokine responses detected against IgE-reactive and non-IgE-reactive NBGA in sensitized and control subjects.

Geometric means and 95% confidence intervals are shown.

**** $p < 0.0001$, *** $p < 0.001$, ** $p < 0.01$, by non-parametric Mann-Whitney t-test. Dotted lines at 20 SFC indicates lower limit of assay detection. We consider 20 SFC/10⁶ PBMC as an operational lower limit of detection in our ELISPOT assay, and is thus used as the “negative” value for donor response, where a lower limit value is required for graphical or

statistical purposes. Each symbol represents the response from an individual subject. NBGA antigens are classified as IgE+ or IgE– based on the gels shown in **Figure 2** and as described in the results

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 4. Immunodominance of Bla-g Epitopes

A) Comparison of the percentage of the total cytokine response per epitope. BLAGA represented by blue circles. Combined BLAGA and NBGA represented by black circles. B) Comparison of the number of epitopes recognized per subject among the Bla-g sensitive subjects.

Figure 5. Changing Magnitude and Polyfunctionality of Responses Among Asthma Severities
Diameter of pie chart is proportional to geometric mean of the total sum of responses for subject group. Values indicated are percentage of total response encompassed by individual cytokine. Red denotes relative proportion of IFN γ responses, blue IL-5, green IL-10, purple, IL-17, and gray IL-21. * $p < 0.05$, ** $p < 0.005$, calculated by non-parametric Mann-Whitney t-test.

Figure 6. Differential Immunodominance of Bla-g Antigens as a Function of Allergic Clinical Status

Percentage response accounted by individual antigens of total cytokine response to all Bla-g Antigens for (A) Control, (B) Allergic Rhinitis, and (C) Asthmatic Sensitized subjects.

“Other” category encompasses antigens accounting individually for <1% of total response for all three groups.

Figure 7. Epitope Sets Reactivity as Function of Asthma Status

Response to epitope set as a percentage of total response for (A) Asthmatic and (B) AR after stimulation with epitope pools following culture with Bla-g extract with corresponding magnitudes of response (in SFC per 10⁶ PBMC) to each pool (C-D). Bars indicate median values (A-B) or geometric means (C-D). Each symbol represents the response from an individual subject.

Table 1
Differential Immunodominance of Bla-g Antigens as a Function of Allergic Clinical Status.

Antigen	Controls			AR			Asthmatic			IA			MMA			SA		
	%	SFC	%	%	SFC	%	%	SFC	%	%	SFC	%	%	SFC	%	%	SFC	%
Bla g 1	5	2	-	-	-	15	188	6	9	44	1044	15	24					
Bla g 2	-	-	12	44	9	44	3	26	33	154	8	12						
Bla g 4	4	54	18	1389	20	85	21	58	33	286	8	11						
Bla g 5	1	2	41	945	29	1704	21	1179	56	1827	31	2872						
Bla g 9	3	314	12	192	47	1275	39	715	67	2281	54	1914						
Bla g 11	2	6	18	170	36	424	30	416	44	676	46	271						
NBGA1	7	290	29	932	47	621	39	700	56	406	62	579						
NBGA2	2	6	12	78	13	78	12	40	11	246	15	53						
NBGA3	-	-	6	21	24	123	15	71	33	85	39	273						
NBGA4	3	30	24	289	16	136	18	151	22	197	8	59						
NBGA5	2	11	12	33	7	19	6	17	-	-	15	37						
NBGA7	1	50	29	194	16	287	18	442	22	96	8	49						
NBGA11	1	15	-	-	-	-	-	-	-	-	-	-						
Enolase	1	9	6	3	6	42	3	27	11	151	8	3						
RACK1	2	30	-	-	9	19	12	31	11	3	-	-						
TPI	2	17	6	13	11	31	6	6	11	83	23	54						

“%” denotes percentage of subjects responding to given antigen. “SFC” denotes the mean magnitude of response per donor. “-” denotes no response. The “Asthmatic” combines the responses across IA, MMA, SA.

Table 2

Functional Response to Immunodominant Antigens Similar Between AR and Asthma Subjects.

<u>Antigen</u>	<u>Group</u>	<u>Percentage of Total Response to Individual Antigen</u>				
		<u>IFNγ</u>	<u>IL-5</u>	<u>IL-10</u>	<u>IL-17</u>	<u>IL-21</u>
Bla-g 4	AR	11.1	57.5	31.1	-	0.3
Bla-g 4	Asthma	17.6	55.4	1.0	20.7	5.4
Bla-g 4	Control	34.4	30.0	-	15.6	19.9
Bla-g 5	AR	5.1	69.0	-	1.2	24.8
Bla-g 5	Asthma	9.3	67.4	16.7	0.4	6.2
Bla-g 5	Control	100.0	-	-	-	-
Bla-g 9	AR	6.6	70.4	3.9	3.9	15.3
Bla-g 9	Asthma	8.1	64.2	11.6	8.8	7.3
Bla-g 9	Control	1.2	31.0	2.5	42.5	22.7
Bla-g 11	AR	5.3	72.5	19.6	-	2.7
Bla-g 11	Asthma	13.9	51.6	6.0	6.5	22.1
Bla-g 11	Control	-	-	-	100.0	-
NBGA1	AR	13.5	67.6	13.8	1.9	3.2
NBGA1	Asthma	17.4	56.3	10.3	8.4	7.6
NBGA1	Control	45.0	25.3	18.1	3.7	7.9

Percentage of cytokine response detected to single antigen for Control, AR, and Asthmatic subjects. “-” denotes no response.